UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Short‐term efficacy of tacrolimus in steroid‐refractory ulcerative colitis – experience in 130 patients

Alimentary pharmacology & therapeutics, 2013-01, Vol.37 (1), p.129-136

2013

Volltextzugriff (PDF)

Vedolizumab in the treatment of chronic, antibiotic‐dependent or refractory pouchitis

Alimentary pharmacology & therapeutics, 2018-03, Vol.47 (5), p.581-587

2018

Volltextzugriff (PDF)

Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2

Clinical and experimental immunology, 2008-03, Vol.151 (3), p.528-535

2008

Volltextzugriff (PDF)

NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression

Gut, 2004-11, Vol.53 (11), p.1658-1664

2004

Volltextzugriff (PDF)

Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus

Alimentary pharmacology & therapeutics, 2010-05, Vol.31 (9), p.1036-1041

2010

Volltextzugriff (PDF)

Probiotic E. coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans

Mucosal immunology, 2009-03, Vol.2 (2), p.166-172

2009

Volltextzugriff (PDF)

Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study

Journal of Crohn's and colitis, 2013-09, Vol.7 (8), p.636-643

2013

Volltextzugriff (PDF)

Benefit of Contrast-Enhanced Ultrasound (CEUS) in the Follow-Up Care of Patients with Colon Cancer: A Prospective Multicenter Study

Ultraschall in der Medizin, 2015-12, Vol.36 (6), p.590-593

2015

Volltextzugriff (PDF)

Ischemic colitis following uncomplicated colonoscopy

Zeitschrift fur Gastroenterologie, 2016-01, Vol.54 (1), p.44-46

2016

Volltextzugriff (PDF)

Letter: short‐term efficacy of tacrolimus in steroid‐refractory ulcerative colitis – authors’ reply

Alimentary pharmacology & therapeutics, 2013-02, Vol.37 (4), p.502-502

2013

Volltextzugriff (PDF)

ABCB1 Single‐Nucleotide Polymorphisms Determine Tacrolimus Response in Patients With Ulcerative Colitis

Clinical pharmacology and therapeutics, 2011-03, Vol.89 (3), p.422-428

2011

Volltextzugriff (PDF)

Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues

Journal of Crohn's and colitis, 2016-01, Vol.10 (1), p.31-37

2016

Volltextzugriff (PDF)

Inflammatory bowel diseases influence major histocompatibility complex class I (MHC I) and II compartments in intestinal epithelial cells

Clinical and experimental immunology, 2013-05, Vol.172 (2), p.280-289

2013

Volltextzugriff (PDF)

Response of refractory colitis to intravenous or oral tacrolimus (FK506)

Inflammatory bowel diseases, 2002-09, Vol.8 (5), p.317-324

2002

Volltextzugriff (PDF)

Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission

The American journal of gastroenterology, 2002, Vol.97 (2), p.377-381

2002

Volltextzugriff (PDF)

Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission

The American journal of gastroenterology, 2002-02, Vol.97 (2), p.377-381

2002

Volltextzugriff (PDF)

Autoreactive Iga Antibodies against the Pancreatic Major Glycoprotein 2 are Associated with Primary Sclerosing Cholangitis and Related Biliary Tract Cancer

Journal of hepatology, 2016, Vol.64 (2), p.S647-S647

2016

Volltextzugriff (PDF)

Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506)

The American journal of gastroenterology, 1998-10, Vol.93 (10), p.1860-1866

1998

Volltextzugriff (PDF)

Defensin-immunology in inflammatory bowel disease

Gastroentérologie clinique et biologique, 2009-06, Vol.33, p.S137-S144

2009

Volltextzugriff (PDF)

Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn’s disease

Alimentary pharmacology & therapeutics, 2009-09, Vol.30 (6), p.621-633

2009

Volltextzugriff (PDF)

Defensins – innate immunity at the epithelial frontier

European journal of gastroenterology & hepatology, 2001, Vol.13 (7), p.771-776

2001

Volltextzugriff (PDF)

6526 POSTER Phase I Study of Definitive Chemoradiation With Cisplatin/5-FU Plus Cetuximab in Unresectable Esophageal Cancer

European journal of cancer (1990), 2011, Vol.47, p.S450-S450

2011

Volltextzugriff (PDF)

Aktualisierte S3-Leitlinie Colitis ulcerosa der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS): AWMF-Register-Nr. 021/009

Zeitschrift für Gastroenterologie, 2018-09, Vol.56 (9), p.1087-1169

2018

Volltextzugriff (PDF)

Clinical trial: cyclophosphamide pulse therapy – a promising therapeutic alternative in refractory Crohn’s disease

Alimentary pharmacology & therapeutics, 2009-06, Vol.29 (12), p.1230-1239

2009

Volltextzugriff (PDF)

Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009

Zeitschrift für Gastroenterologie, 2023-08, Vol.61 (8), p.1046-1134

2023

Volltextzugriff (PDF)

1 – 25 von 152

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(139)
Mit Volltextzugriff
(90)

Publikationsform

Sprache

Englisch
(107)
Deutsch
(50)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(78)
Science & Technology
(74)
Life Sciences & Biomedicine
(72)
Gastroenterology & Hepatology
(48)
Biological And Medical Sciences
(38)
Male
(37)
Adult
(36)
Female
(35)
Medical Sciences
(34)
Middle Aged
(34)
Aged
(24)
Gastroenterology. Liver. Pancreas. Abdomen
(23)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(22)
Other Diseases. Semiology
(21)
Inflammatory Bowel Disease
(20)
Treatment Outcome
(20)
Crohn's Disease
(16)
Pharmacology. Drug Treatments
(16)
Adolescent
(15)
Immunosuppressive Agents - Therapeutic Use
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Short‐term efficacy of tacrolimus in steroid‐refractory ulcerative colitis – experience in 130 patients

Vedolizumab in the treatment of chronic, antibiotic‐dependent or refractory pouchitis

Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2

NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression

Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus

Probiotic E. coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans

Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study

Benefit of Contrast-Enhanced Ultrasound (CEUS) in the Follow-Up Care of Patients with Colon Cancer: A Prospective Multicenter Study

Ischemic colitis following uncomplicated colonoscopy

Letter: short‐term efficacy of tacrolimus in steroid‐refractory ulcerative colitis – authors’ reply

ABCB1 Single‐Nucleotide Polymorphisms Determine Tacrolimus Response in Patients With Ulcerative Colitis

Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues

Inflammatory bowel diseases influence major histocompatibility complex class I (MHC I) and II compartments in intestinal epithelial cells

Response of refractory colitis to intravenous or oral tacrolimus (FK506)

Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission

Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission

Autoreactive Iga Antibodies against the Pancreatic Major Glycoprotein 2 are Associated with Primary Sclerosing Cholangitis and Related Biliary Tract Cancer

Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506)

Defensin-immunology in inflammatory bowel disease

Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn’s disease

Defensins – innate immunity at the epithelial frontier

6526 POSTER Phase I Study of Definitive Chemoradiation With Cisplatin/5-FU Plus Cetuximab in Unresectable Esophageal Cancer

Aktualisierte S3-Leitlinie Colitis ulcerosa der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS): AWMF-Register-Nr. 021/009

Clinical trial: cyclophosphamide pulse therapy – a promising therapeutic alternative in refractory Crohn’s disease

Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009

Suchergebnisse filtern